What MiMedx Group (MDXG) Said on Its Q3 Earnings Call

MiMedx Group NASDAQ: MDXG reported third-quarter net sales of $62 million, down 45% from a year earlier, as continued disruption in the wound care market offset growth in its surgical business. The company said surgical revenue rose 9% year over year to $40 million, while wound care revenue declined 71% to $22 million following Medicare reimbursement changes that took effect at the beginning of 2026.

MarketBeat • 21 hours ago

MiMedx Group, Inc. (MDXG) Q3 2026 Earnings Call Transcript

MiMedx Group, Inc. (MDXG) Q3 2026 Earnings Call Transcript

Seeking Alpha • a day ago

MIMEDX Announces Third Quarter 2026 Operating & Financial Results

Reports Continued Double-Digit Year-Over-Year Volume Growth for Surgical Franchise Delivers Wound Care Center Volume Growth Both Sequentially and Year-Over-Year Obtained Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter During Quarter Today Announced Patent License Agreement, Underscoring Strength of IP Portfolio Management to Host Conference Call Today, October 28, 2026, at 4:30 PM ET MARIETTA, Ga., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced operating and financial results for the third quarter of 2026.

GlobeNewsWire • Oct 28, 2026

MIMEDX Announces $25 Million Patent License Agreement

MARIETTA, Ga., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into a license agreement with a wound care competitor that resolves allegations of infringement of MIMEDX's patents.

GlobeNewsWire • Oct 28, 2026

MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026

MARIETTA, Ga., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, October 28, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.

GlobeNewsWire • Oct 14, 2026

MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter

Court Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified as a Biological Product

GlobeNewsWire • Sep 23, 2026

Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sanara MedTech Inc. (NasdaqCM: SMTI) to MiMedx Group, Inc. (NasdaqCM: MDXG). Under the terms of the proposed transaction, shareholders of Sanara will receive $33.00 in cash and 0.4735 shares of MiMedx common stock for each share of Sanara that they own. KSF is seeking to determine whether this consi.

Business Wire • Sep 10, 2026

MIMEDX to Participate in Upcoming Investor Conferences

MARIETTA, Ga., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:

GlobeNewsWire • Sep 8, 2026

MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript

MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jul 30, 2026

MiMedx Group Q2 Earnings Call Highlights

MiMedx Group NASDAQ: MDXG said it has agreed to acquire Sanara MedTech in a transaction valued at $35 per Sanara share, a deal the company expects to close by the end of 2026. The announcement accompanied MiMedx's second-quarter results, which showed sequential improvement in its wound-care business and continued growth in surgical sales.

MarketBeat • Jul 29, 2026